The Filing Desk

Bicycle Therapeutics

BCYC · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

BCYC · Last close · November 19, 2026
$3.05
Value Bicycle Therapeutics yourself

Bicycle Therapeutics' revenue rose 105.8% to $73 million in fiscal 2025. Its operating margin was −340.4%, up from −595.0% a year earlier. Free cash flow was −$252 million. The diluted share count rose 19.0%.

Bicycle Therapeutics plc Latest fiscal year ended December 31, 2025 10-K filed March 17, 2026 · 0001104659-26-028971 Updated
Revenue
$73M
105.8%
Operating margin
−340.4%
254.6 pts
Net income
−$219M
 
Free cash flow
−$252M
 
Return on equity
−31.2%
2.2 pts
Market cap
$214M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Bicycle Therapeutics does

Bicycle Therapeutics is a drug developer, based in Cambridge, England, that has no approved medicines yet. Its experimental drugs are built from Bicycle molecules: small, lab-made chains of amino acids folded into two loops so they latch tightly onto a chosen target. It attaches them to a toxin that kills tumor cells, or to a radioactive payload, and is testing them mainly against cancer.

Its main candidate, nuzefatide pevedotin, is in clinical trials in patients with advanced solid tumors and pancreatic cancer. A radioactive candidate, BT1702, is in the safety studies needed before human trials can start. In March 2026 the company said it would scale back work on zelenectide pevedotin, a drug tested in bladder, breast and lung cancers, and stop developing a third drug, BT7480, on its own. It is cutting about 30% of its workforce.

So far its revenue has come from research deals with larger drug makers, including Bayer, Novartis, Ionis and Genentech, which pay it to find Bicycle molecules for their own programs. Collaboration revenue rose by $37.3 million in 2025, mostly because Novartis and Bayer ended deals and the remaining payments were counted. The company had $628.1 million in cash at the end of 2025 and 288 employees, 191 of them in the United Kingdom.

Its biggest risks, as it describes them

  • A long history of losses, and the chance that it never becomes profitable.
  • It depends on a few drug candidates that may fail in trials or never win approval.
  • Its Bicycle drugs are a new kind of medicine and may face extra scrutiny from regulators.
  • It may need to raise more money, which could dilute shareholders or force it to cut programs.
  • Competitors may bring out cancer drugs that work better, are safer or cost less.
From Bicycle Therapeutics's annual report on Form 10-K, filed March 17, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Bicycle Therapeutics lost money in fiscal 2025: a net loss of $219 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments439339526880628
Debt incl. finance leases303031——
Net debt (negative means net cash)−409−309−496——
Net debt to EBITDA—————
Debt to equity0.1x0.1x0.1x——
Interest coverage−22.0x−34.9x−58.2x−121.3x−1,199.3x
Current ratio12.7x6.9x8.1x13.8x12.0x
Quick ratio12.7x6.9x8.1x13.8x12.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Bicycle Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Bicycle Therapeutics shares on the open market, and 7 insiders sold $458,694, $63,505 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 6, 2026Kevin LeeChief Executive Officer, DirectorSold1,737$4.31$7,486Form 4
Jul 6, 2026Michael SkynnerChief Scientific OfficerSold532$4.31$2,293Form 4
Jul 6, 2026Jennifer Scott PerryChief Operating OfficerSold plan376$4.34$1,631Form 4
Jul 6, 2026Michael Charles Ferguson HannayChief Prod & Supply Chain OffSold255$4.31$1,099Form 4
Jul 6, 2026Travis Alvin ThompsonChief Financial OfficerSold104$4.31$448Form 4
Jul 2, 2026Kevin LeeChief Executive Officer, DirectorSold5,905$4.27$25,214Form 4
Jul 2, 2026Michael SkynnerChief Scientific OfficerSold1,859$4.27$7,938Form 4
Jul 2, 2026Michael Charles Ferguson HannayChief Prod & Supply Chain OffSold1,506$4.27$6,431Form 4
Jul 2, 2026Jennifer Scott PerryChief Operating OfficerSold plan1,036$4.27$4,424Form 4
Jul 2, 2026Travis Alvin ThompsonChief Financial OfficerSold819$4.27$3,497Form 4
Apr 6, 2026Kevin LeeChief Executive Officer, DirectorSold1,716$5.05$8,666Form 4
Apr 6, 2026Michael SkynnerChief Scientific OfficerSold525$5.05$2,651Form 4
The latest 12 of 32 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 8——
Rule of 40−149.1%−439.7%−241.4%
Altman Z''2.217.205.27
Accruals ratio−23.9%−0.6%3.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assetsPass——
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score4 of 8——
Companies that report no gross profit are scored on the other eight.

Compare

Put Bicycle Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Bicycle TherapeuticsFY25105.8%−340.4%−347.2%———
CompugenFY25161.1%43.0%43.0%———Compare
CellectisFY2575.8%−45.3%−57.2%———Compare
Recursion PharmaceuticalsFY2526.9%−867.9%−506.5%−117.2%—4Compare
AbCellera BiologicsFY25160.6%−289.0%−231.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue2714101214273573
Revenue growth—246.4%93.4%−24.7%12.6%23.6%86.5%30.8%105.8%
Gross profit—————————
Research and development122126334582156173240
Operating income−16−22−26−52−66−117−190−210−247
Net income−16−22−31−51−67−113−181−169−219
Diluted EPS (US$)−48.81−49.78−2.77−2.66−2.67−3.80−5.08−2.90−3.16
Diluted shares (millions)0011192530365869
Cash flow
Cash from operations−1−26−29−18−15−86−61−165−250
Capital expenditure1121219312
Free cash flow−3−27−30−19−17−105−64−166−252
Dividends paid000000000
Share buybacks000000000
Acquisitions000000000
Stock-based compensation01361227323840
Balance sheet at fiscal year end
Cash and short-term investments68000439339526880628
Debt incl. finance leases———14303031——
Total assets—82110161480411595957718
Total liabilities—291766134140224164108
Shareholders' equity−47−709396346271371793610
Margins and ratios
Gross margin—————————
Operating margin−787.0%−304.7%−190.6%−500.1%−561.0%−806.6%−704.1%−595.0%−340.4%
Net margin−789.3%−306.1%−221.8%−490.9%−571.2%−779.4%−669.7%−479.2%−301.7%
Free cash flow margin−122.7%−382.1%−218.6%−182.8%−143.8%−726.7%−235.6%−470.5%−347.2%
Rule of 40 (growth + FCF margin)—−135.7%−125.2%−207.5%−131.2%−703.0%−149.1%−439.7%−241.4%
Return on capital—————————
Return on equity——−261.9%−54.1%−30.2%−36.5%−56.3%−29.0%−31.2%
Return on assets——−31.9%−37.6%−20.9%−25.3%−35.9%−21.8%−26.1%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Bicycle Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Bicycle Therapeutics.